Assuming curative intent, both the EAU and NCCN recommend RC as the treatment of choice for MIBC.
The EAU further recommends pelvic lymph node dissection following RC to improve survival after RC, although no data are currently available to support this recommendation.
Along with RC as the primary treatment for all muscle-invasive disease, the NCCN strongly advises cisplatin-based neoadjuvant chemotherapy (category 1 recommendation)—particularly for patients with hydronephrosis, vascular/lymphatic invasion, extravesical disease, or aberrant histologic variants.
Learn more about EUA and the NCCN guideline recommendations for the treatment of bladder cancer.
Medscape © 2020 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Kyle A. Richards. Fast Five Quiz: Bladder Cancer Management - Medscape - Jan 13, 2020.